Canadian technology that could transform how we treat cancer

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Read this article, published in the Toronto Star, about Montreal-based start-up Jenthera Therapeutics who are developing in vivo gene editing that can directly modify a person’s DNA and fine tune immune cells to find and attack specific types of cancer.

Jenthera presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Tenomix secures an all-Canadian oversubscribed Seed round of $2M to advance a breakthrough cancer care robotics system
Next

HDAX among ten exciting U of T-affiliated start-ups to keep an eye on in 2024